Hiv-1 env fusion peptide immunogens and their use
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Servic
InventorsPeter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
Life of this patent
Estimating the term…
Abstract
Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
Claims20
An immunogen, comprising a human immunodeficiency virus type 1 (HIV-1) Env fusion peptide conjugated to a carrier protein by a heterologous linker, wherein:
- the HIV-1 Env fusion peptide consists of the amino acid sequence of residue 512 to one of residues 517-521 of HIV-1 Envelope (Env) protein, wherein the HIV-1 Env residue positions correspond to a HXB2 reference sequence set forth as SEQ ID NO:
- 154;
- the carrier is a tetanus toxoid heavy chain C fragment;
- and
- the immunogen elicits a neutralizing immune response to HIV-1 in a subject.
Dependencies are inferred from the claim text.